Dilated cardiomyopathies

Vasculogenic competency in idiopathic dilated cardiomyopathy.

Idiopathic dilated cardiomyopathy (IDCM) represents the third most common cause of heart failure and the most frequent form of primary myocardial disease. In recent years, the ICREC research group has extensively examined the marked myocardial vascular derangements associated with disease progression and poor outcomes in the patients afflicted by IDCM. Our findings have re-examined the IDCM pathophysiology as a downstream complication of cardiac vasculature that contribute actively to myocyte damage.

We are currently committed in further studying the regulatory cellular and molecular mechanisms governing the activation, migration and myocardial incorporation of circulating angiogenic progenitor cells focusing in potential alterations found in these patients.

Roura S, Bayes-Genis A. Vascular dysfunction in idiopathic dilated cardiomyopathy. Nat Rev Cardiol. 2009 Sep;6(9):590-8. Epub 2009 Jul 28. Review.

Intracellular signaling associated to lipid raft domains in idiopathic dilated cardiomyopathy.

Lipid rafts, which are domains within the plasma membrane enriched in cholesterol and lipids with saturated acyl chains, participate actively in multiple cellular processes such as antigen and cytokines presentation, intracellular signaling, and cell adaptation to environmental factors.

Recently, the ICREC group has initiated the isolation and characterization of lipid rafts from human myocardium, and the study of the contribution of distinct lipid raft-associated receptors and downstream effectors in the pathogenesis and progression of IDCM.

Roura S, Gámez-Valero A, Lupón J, Gálvez-Montón C, Borràs FE, Bayes-Genis A. Proteomic signature of circulating extracellular vesicles in dilated cardiomyopathy. Lab Invest. 2018 Oct;98(10):1291-1299.

Roura S, Gálvez-Montón C, de Gonzalo-Calvo D, Valero AG, Gastelurrutia P, Revuelta-López E, Prat-Vidal C, Soler-Botija C, Llucià-Valldeperas A, Perea-Gil I, Iborra-Egea O, Borràs FE, Lupón J, Llorente-Cortés V, Bayes-Genis A. Extracellular vesicles do not contribute to higher circulating levels of soluble LRP1 in idiopathic dilated cardiomyopathy. J Cell Mol Med. 2017 Nov;21(11):3000-3009.

Santiago Roura, Carolina Gálvez-Montón, Josep Lupón, Antoni Bayes-Genis. Idiopathic dilated cardiomyopathy: Molecular basis and distilling complexity to advance. Chapter 6. Cardiomyopathies - Types and Treatments. Edited by Mehmet kaan Kirali. InTech. 2017.

Roura S, Gálvez-Montón C, Fernández MA, Lupón J, Bayes-Genis A. Circulating Endothelial Progenitor Cells: Potential Biomarkers for Idiopathic Dilated Cardiomyopathy. J Cardiovasc Transl Res. 2016 Feb;9(1):80-4.

Roura S, Gálvez-Montón C, Bayes-Genis A. Umbilical cord blood-derived mesenchymal stem cells: new therapeutic weapons for idiopathic dilated cardiomyopathy? Int J Cardiol. 2014 Dec 20;177(3):809-18.

Roura S, Cal R, Gálvez-Montón C, Revuelta-Lopez E, Nasarre L, Badimon L, Bayes-Genis A, Llorente-Cortés V. Inverse relationship between raft LRP1 localization and non-raft ERK1,2/MMP9 activation in idiopathic dilated cardiomyopathy: potential impact in ventricular remodeling. Int J Cardiol. 2014 Oct 20;176(3):805-14.

Roura S, Gálvez-Montón C, Pujal JM, Casani L, Fernández MA, Astier L, Gastelurrutia P, Domingo M, Prat-Vidal C, Soler-Botija C, Llucià-Valldeperas A, Llorente-Cortés V, Bayes-Genis A. New insights into lipid raft function regulating myocardial vascularization competency in human idiopathic dilated cardiomyopathy. Atherosclerosis. 2013 Oct;230(2):354-64.

Roura S, Bayes-Genis A. Vascular dysfunction in idiopathic dilated cardiomyopathy. Nat Rev Cardiol. 2009 Sep;6(9):590-8.

Roura S, Planas F, Prat-Vidal C, Leta R, Soler-Botija C, Carreras F, Llach A, Hove-Madsen L, Pons Lladó G, Farré J, Cinca J, Bayes-Genis A. Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation. Eur J Heart Fail. 2007 Oct;9(10):995-1002